What the safety record actually shows

Across more than 19,000 treated units, ChondroFiller® liquid has produced zero serious adverse device effects (SADEs) — a complication rate of approximately 0% in pooled clinical data. That figure does not come from promotional material; it originates from Meidrix Biomedicals GmbH's Clinical Evaluation Report (CER Version 09, dated 30 April 2025), a mandatory regulatory submission under EU Medical Device Regulation for CE Class III implants. Class III is the highest-risk category under that framework, meaning the regulatory bar for this kind of evidence is substantial.

The 19,000-case dataset spans eight joint types — knee, hip, shoulder, ankle, wrist, elbow, foot, and hand — and draws on three evidence streams: post-market clinical follow-up (PMCF) studies, prospective cohort studies with structured follow-up intervals, and multinational registry data. All sources are manufacturer-sponsored and observational in design; no blinded randomised controlled trial has been published for ChondroFiller® liquid, and that distinction matters when weighing the evidence.

Even so, volume itself carries inferential weight. When genuinely rare device-related harms exist, they tend to surface across datasets of this scale. A consistent absence of SADEs across 19,000 real-world cases is a meaningful safety signal — not a guarantee, but a substantive one, drawn from post-market experience rather than controlled laboratory conditions.

Common side effects and what to expect after injection

Some aching and puffiness around the treated joint in the first day or two is expected and usually settles quickly. Because ChondroFiller® liquid gels in situ after injection, localised swelling, a temporary pain flare, and mild stiffness are a normal part of that process — not a sign that something has gone wrong. A small number of patients also notice minor joint crepitus (a faint clicking or grinding sensation), which typically carries no meaningful impact on how the joint recovers.

Infection is a risk with any intra-articular injection, not a concern specific to this device. When the treatment is delivered as an ultrasound-guided outpatient injection — as in the current service pathway — accurate image-guided placement and strict sterile technique substantially reduce that risk. No additional precautions beyond those standard to any joint injection are required.

For the common expected effects, no intervention is needed; knowing to anticipate them beforehand prevents unnecessary concern. Two signals do warrant prompt clinical review: pain that continues to escalate rather than taper beyond 48–72 hours post-injection, or the onset of fever. Either should prompt a call to the treating team rather than a period of watchful waiting.

Two risks that shape patient selection

Two risks sit above the level of routine transient effects and directly shape which patients are offered ChondroFiller® liquid — but both are preventable through screening and procedural discipline rather than being unpredictable device failures.

The scaffold is derived from murine (rat/mouse) Type I collagen. For the overwhelming majority of patients this presents no issue, but anyone with a known hypersensitivity to collagen or rodent-derived proteins is contraindicated. Pre-treatment screening for this is a standard step in the initial consultation — a straightforward allergy history question rather than a burdensome process — and it is the main reason specialist patient selection sits upstream of treatment, not as an afterthought.

The second risk is fibrous tissue formation: if the cartilage defect is overfilled during injection, the scaffold can produce scar-like tissue that may affect how the repair matures. Avoiding this comes down to precise dosing matched to the actual defect size — a clinical skill that ultrasound-guided placement actively supports, since real-time imaging allows the treating clinician to control volume delivery accurately as the gel is placed.

When both protocols are followed — correct patient screening and accurate dosing — neither risk has contributed to a single serious adverse device effect across the 19,000-plus treated cases recorded in the CER.

Reoperation rate in context

Reoperation rate — how often a patient needs further intervention because the original treatment did not hold — captures real-world durability in a way that symptom scores alone do not, and it is one of the most practically useful figures in any cartilage comparison.

These figures come from observational datasets covering different patient populations and delivery routes rather than a controlled head-to-head trial. With that in mind: ChondroFiller® liquid sits at approximately 3–8% in the published dataset. Microfracture produces rates of up to 41%; ACI/MACI (autologous chondrocyte implantation) up to 37%. The patient profiles, defect grades, and surgical contexts behind each figure are not uniform, so the comparison is directionally informative rather than a definitive verdict.

Even so, a gap of this scale is clinically meaningful rather than marginal. For a patient weighing an ultrasound-guided injectable scaffold pathway against more invasive surgical alternatives, reoperation rate translates into something tangible: the probability of needing a further procedure — with all the disruption, recovery time, and uncertainty that entails. It is the kind of number worth asking about at consultation.

What MRI imaging shows about how the scaffold integrates

MRI evidence provides the most objective window into what the scaffold is actually doing inside the joint. Post-treatment scans consistently show a reduction in bone marrow oedema (localised bone swelling around the defect), diminished joint fluid build-up, and progressive widening of joint space — structural changes that reflect integration rather than simple symptom suppression.

Clinicians use a dedicated MRI scoring system called MOCART to quantify how well the treated area is filling and blending with the surrounding cartilage. Scores run from 0 to 100; anything above 80 indicates good defect fill with native tissue integration. Across European cohorts, ChondroFiller® liquid produces MOCART scores of 81.6 to 84.3 — consistently clearing that threshold.

The trajectory matters as much as the final number. At four weeks post-injection, scores sit around 65.3 — adequate early fill, but the repair is still developing. By twelve months, the same patients reach 81.6. That progression reflects how the scaffold actually works: it acts as a temporary framework that the body's own repair cells move into over the following months, gradually filling the defect through a process known as acellular matrix-induced chondrogenesis. The scaffold itself is not adding new cartilage — it is supporting the patient's own biology to do so.

In a prospective controlled trial of Grade IV osteoarthritis patients, no serious adverse events were recorded alongside these structural improvements, reinforcing the biocompatibility picture that imaging alone suggests.

Which patients this safety profile applies to

The ~0% complication rate documented across 19,000+ treatments does not apply universally. It holds within a clearly defined clinical envelope: patients with focal Grade III or IV cartilage defects, intact surrounding cartilage borders, and anatomy suited to precise scaffold placement. Extending that figure to advanced diffuse osteoarthritis, or to presentations with compromised perilesional tissue, would be a misreading of the evidence — the record reflects protocol fidelity as much as product safety.

This is why patient selection is not a preliminary administrative step but a direct determinant of the outcome. The zero-SADE record exists because the population producing it was assessed carefully before treatment, not because ChondroFiller® liquid is risk-free in any anatomical context.

For patients at the decision stage, the practical implication is straightforward: a thorough clinical assessment — including imaging review and, where biomechanical loading patterns are relevant, objective motion analysis — will determine whether their defect profile sits within the validated range. If it does, the evidence reviewed here suggests they are entering a well-characterised safety window. If it does not, an honest assessment will say so, and a different pathway will be the more appropriate recommendation.